Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price20.14 USD
Fair value21.85
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Distribution20.14+0.0% to today
2026-09-13Read Markup21.59-6.7% to today
2026-08-13Read Accumulation18.38+9.6% to today ✓
2026-07-02Read Markdown15.31+31.5% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Sarepta Therapeutics, Inc. holds its Markdown at $20.14. The statistical read favours the sellers, held for 14 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 14 days
Price at the screen
$20.14
Valuation
N/A trailing · 7.65 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.26
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
31.04%
Below 33%
Interest-bearing debt is just 31.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.13%
Below 33%
Cash held in interest-bearing accounts and securities is 4.1% of assets, under the one-third limit.
Pass
Receivables
35.81%
Below 49%
Money owed to the company is 35.8% of assets, under the 49% limit.
Pass
Revenue purity
1.67%
Below 5%
Only 1.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Sarepta Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 8.5% margin of safety to the base estimate.
Third-party analyst targets: 23 covering, consensus Hold. The average target sits −1% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease hopes meet shrinking revenue
Imagine families waiting on a single genetic therapy to change a child's life. Sarepta develops exactly those RNA and gene treatments for rare conditions, yet the business shows no lift. We pass because revenue is falling and the numbers offer nothing to build a case around.
Forward earnings sit at seven times but top line slipped two percent, profit margins reach only three percent and return on equity is five percent. Analysts call it a hold with a twenty dollar median target, well below our fair value mark. The ethical screen clears yet opportunity stays at none.
An unknown moat in a trial heavy field leaves the firm exposed to sudden setbacks that can wipe out years of work. Low returns and flat growth point to a business that has yet to prove durable scale. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SRPT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (23 analysts) rates it hold, with a mean price target of $22.
2026-09-13Markup · changed$21.59+17.5%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 17.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (23 analysts) rates it hold, with a mean price target of $22.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 20.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (23 analysts) rates it hold, with a mean price target of $22.
2026-07-18Markdown$15.31+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 61%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (23 analysts) rates it hold, with a mean price target of $22.
2026-07-03Markdown$15.31+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$15.31Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
